Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Good exposure

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Mar 10, 2022 5:10pm

102 Views

Post# 34504594

RE:Good exposure

I could not access your link but I think that is from October 2019, just before the whole world got to know who Dr. Fauci was!

scarlet1967 wrote:
FDA-approved drug reverses signs of liver disease in people with HIV

"Many people living with HIV have overcome larger barriers to live healthier lives, and while many still experience liver disease, Nissi Director Anthony S. Fauci, MD" is encouraging for Tesamorelin, already approved to treat other comorbidities Symptomatic HIV drug may be effective in addressing nonalcoholic fatty liver disease. "

https://www.eastinstrument.com/shengmingkexue/2022-03/1015552.html